Navigation Links
BioRestorative Therapies, Inc. Begins Trading Under New Name and Symbol ("BRTX")
Date:9/19/2011

JUPITER, Fla., Sept. 19, 2011 /PRNewswire/ -- BioRestorative Therapies, Inc. (OTCQB: BRTX) (the "Company"), formerly known as Stem Cell Assurance, Inc., today announced that its common stock is now trading on the OTCQB market under its new name, BioRestorative Therapies, Inc., and that the trading symbol for its common stock has been changed from "SCLZ" to "BRTX."

Mark Weinreb, the Company's Chairman and Chief Executive Officer, said, "The commencement of trading using our new symbol and name is one more positive step in positioning BRT as an emerging player in the stem cell arena. This helps signal the beginning of our branding of the Company and the initiatives we are pursuing."

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc.'s goal is to become a medical center of excellence using cell and tissue protocols, primarily involving a patient's own (autologous) adult stem cells (non-embryonic), allowing patients to undergo cellular-based treatments. In June 2011, the Company launched a platform technology that involves the use of a brown fat cell-based therapeutic/aesthetic program, known as the ThermoStem Program.  The ThermoStem program will focus on treatments for obesity, weight loss, diabetes, hypertension, other metabolic disorders and cardiac deficiencies and will involve the study of stem cells, several genes, proteins and/or mechanisms that are related to these diseases and disorders.  As more and more cellular therapies become standard of care, the Company believes its strength will be its focus on the unity of medical and scientific explanations for clinical procedures and outcomes for future personal medical applications.  The Company also plans to offer and sell facial creams and products under the Stem Pearls™ brand.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:
Mark Weinreb
CEO
Tel: (561) 904-6070
Fax: (561) 429-5684


'/>"/>
SOURCE BioRestorative Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioRestorative Therapies, Inc. Announces Upgrade to OTCQB Market
2. Stem Cell Assurance, Inc. Announces Change of Name to BioRestorative Therapies, Inc.
3. Course correction needed for Alzheimers therapies, experts warn
4. As New Data Wave Begins, a Gene Study in One Disease Discovers Mutations in an Unrelated Disease
5. Austen BioInnovation Institute in Akron Begins Work on Roadmap for First U.S. Accountable Care Community
6. Vaxart Begins First Oral Vaccine Clinical Trial
7. BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review
8. Tissue Genesis Begins FDA-Approved Clinical Trial
9. Wind tunnel begins operations at Empa in Duebendorf
10. Biotech Begins Year on a Quiet, but Optimistic Note
11. USDA scientists discover how foot-and-mouth disease virus begins infection in cattle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017 /PRNewswire/ - The Fight Against Cancer ... Research (OICR) are pleased to report that Fusion Pharmaceuticals ... with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) ... groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as ... ...
(Date:2/23/2017)... -- In Atlanta, it seems everyone has a chance to express ... an expressive and dynamic community unlike any other. The businesses ... it. With their newest salon in ... carry on that tradition with a unique, fresh approach to ... is the newest of 13 nationwide locations, each of them ...
(Date:2/23/2017)... 2017  Imanis Life Sciences announced today the ... vaccinia viruses for virotherapy research. These viruses are ... proprietary, vaccinia virus-based technology platform for research use. ... a partnership with Genelux to offer researchers, for ... use in research," said Dr. Kah Whye ...
(Date:2/23/2017)... ... February 23, 2017 , ... Baltimore ... multiple immunoassay-based threat detection technologies by researchers from the Pacific National Northwest ... detection technology was found to have the best level of detection (LOD) ...
Breaking Biology Technology:
(Date:2/10/2017)... , Feb 10, 2017 ... new report "Personalized Medicine - Scientific and Commercial Aspects" ... ... personalized medicine. Diagnosis is integrated with therapy for selection of ... on early detection and prevention of disease in modern medicine. ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
Breaking Biology News(10 mins):